Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2026, 10:00 (CEST) to 23 September 2026, 12:00 (CEST)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 October 2026, 10:00 (CEST) to 21 October 2026, 12:00 (CEST)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 November 2026, 10:00 (CET) to 18 November 2026, 12:00 (CET)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - December 2026, European Medicines Agency, Amsterdam, the Netherlands, from 16 December 2026, 10:00 (CET) to 16 December 2026, 12:00 (CET)

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Date of authorisation: 10/06/2008, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Imlygic, talimogene laherparepvec, Date of authorisation: 16/12/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Viatris, eltrombopag, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 16, Status: Authorised